
## Paolina Salamone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1935091/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	NADPH oxidase (NOX2) activity is a modifier of survival in ALS. Journal of Neurology, 2014, 261, 2178-2183.	3.6	36
2	Amyotrophic lateral sclerosis caregiver burden and patients' quality of life during COVID-19 pandemic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 146-148.	1.7	15
3	G-CSF (filgrastim) treatment for amyotrophic lateral sclerosis: protocol for a phase II randomised, double-blind, placebo-controlled, parallel group, multicentre clinical study (STEMALS-II trial). BMJ Open, 2020, 10, e034049.	1.9	7
4	Effects of intracellular calcium accumulation on proteins encoded by the major genes underlying amyotrophic lateral sclerosis. Scientific Reports, 2022, 12, 395.	3.3	7
5	Brain <sup>18</sup> fluorodeoxyglucose-positron emission tomography changes in amyotrophic lateral sclerosis with <i>TARDBP</i> mutations. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1021-1023.	1.9	4
6	A novel splice site FUS mutation in a familial ALS case: effects on protein expression. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-9.	1.7	2
7	Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 424-429.	1.7	2
8	Tailoring patients' enrollment in ALS clinical trials: the effect of disease duration and vital capacity cutoffs. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 108-115.	1.7	1